HELIXPAN

The HELIXPAN test is recommended for individuals who wish to proactively monitor their long-term health by assessing early genomic alterations associated with the development of solid tumors. It is particularly suitable for people who:

• lead a generally healthy lifestyle and follow balanced dietary and behavioral habits;

• are not exposed to significant environmental or occupational pollution;

• have no symptoms or medical history that would require a disease-specific surveillance program;

• wish to complement routine medical check-ups with a genomic approach capable of detecting early signs of somatic instability;

• are interested in a preventive strategy based on the annual monitoring of somatic mutations to support early detection and personalized risk assessment.

HELIXPAN is ideal for those who aim to maintain control over their genomic health, even in the absence of known risk factors, by adding a cutting-edge molecular tool to their preventive routine.

HELIXPAN represents a modern approach to cancer prevention, based on the objective evaluation of somatic mutations rather than on subjective or family-based risk assessments. Through liquid biopsy and Next Generation Sequencing (NGS), the test identifies and quantifies acquired mutations that may reflect early genomic instability—one of the earliest measurable indicators associated with the development of solid tumors.

Its true strength lies in the ability to repeat the analysis annually, allowing the monitoring of mutation frequencies over time. By comparing results year after year, HELIXPAN provides a dynamic view of the patient’s genomic stability, enabling the early detection of emerging alterations and supporting a more precise and personalized preventive strategy.